Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
GlobalData on MSN12d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program
Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...
BioSpace12d
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Intellia Gets RMAT Designation From FDA For Nex-z In ATTR Amyloidosis With Polyneuropathy; Stock Up
Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...
SussexWorld on MSN5d
Crawley man to complete epic fundraising quest for Amyloidosis
This Friday, local man David Tasker will complete the last of his ten challenges to raise money for amyloidosis research and ...
BioPharma Dive8d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
The Cool Down on MSN25m
Researchers raise concerns over future of quickly disappearing feline species: 'A total crash of the population'
The most important aspect of protecting vulnerable species, however, is funding. Researchers raise concerns over future of ...
Medical Xpress29d
Expert explains cardiac amyloidosis
Cardiac amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins. These amyloids can gather in different organs throughout the ...
Seeking Alpha7d
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder transthyretin cardiac amyloidosis in a potential setback to Pfizer (NYSE ...